Blast Off For Peregrine Pharma on Lung Cancer Update

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is surging on news updating its non-small cell lung cancer trial. The company said that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC).

The blinded study evaluated two dose levels of bavituximab given with docetaxel versus docetaxel plus placebo (control arm). Today's rep[ort on the interim data showed a statistically significant improvement in overall survival and a doubling of median overall survival in the bavituximab-containing arms compared to the control arm.

Joseph Shan, vice president of clinical and regulatory affairs at Peregrine said, "The quality of this data gives us a solid foundation for designing a phase III trial with an increased probability of success. We are planning for an end-of-phase II meeting with the FDA as we plan to initiate this trial by mid-2013."

Peregrine shares are now up a monster 49% at $4.59 on more than 7 million shares as of 1:22 PM EST and the market capitalization rate here is a mere $355 million.


Filed under: 24/7 Wall St. Wire, Biotech, Drug companies, Healthcare Tagged: PPHM
Read Full Story

Can't get enough personal finance tips?

Sign up for Finance Report by AOL and get everything from consumer news to money tricks delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.